Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 497

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 497
---
 (50, 69) |
| 75th quantile (95% CI)(2)                                                                                                                   |     |    143 (141, 143) |     |         | 126 (87, 146) |
| Comparison to Placebo(3) (Hazard ratio [95% CI]):                                                                                           |     | 0.68 (0.54, 0.86) 
           P=0.001 |     |         |               |

| (1) | Censored patients are the following: (1) patients who do not receive a repeat injection of SP-102 and (2) patients who discontinued the study prior to Week 20 without receiving a repeat injection. |

| (2) | Quartiles are estimated using Kaplan-Meier estimation. |

| (3) | A Cox proportional hazards model was utilized to test the treatment difference while adjusting for site and Pain Catastrophizing Scale (<30 or ≥30). |

CI: confidence interval; ITT: intent-to-treat(randomized population); SD: standard deviation Responder Analysis (Change from Baseline in Mean NPRS, Average Daily Pain in Affected Leg) (1)– ITT Population

|                                              |     | SP-102            
 N=202             |     | Placebo    
 N=199      |
| 30% reduction                                |     | 88 (43.6%)        |     | 57 (28.6%) |
| Chi-Square                                   |     | P=0.002           |     |            |
| Logistic regression(2) (odds ratio [95% CI]) |     | 1.96 (1.28, 2.98) 
 P=0.002           |     |            |
| 50% reduction                                |     | 58 (28.7%)        |     | 41 (20.6%) |
| Chi-Square                                   |     | P=0.060           |     |            |
| Logistic regression(2) (odds ratio [95% CI]) |     | 1.58 (0.99, 2.52) 
 P=0.055           |     |            |

303

| (1) | Patients that discontinued or have missing scores at Week Four were considered non-responders. |

| (2) | Logistic regression models with treatment (SP-102 or placebo), site, and Pain Catastrophizing Scale group (<30 or ≥30), and